乳がん診断薬市場規模、シェア、成長分析、タイプ別、製品別、がんタイプ別、用途別、エンドユーザー別、地域別 - 産業予測、2025-2032年

乳がん診断薬市場規模は2023年に56億米ドル、予測期間（2025-2032年）のCAGRは7.8%で、2024年の60億4,000万米ドルから2032年には110億1,000万米ドルに成長すると予測されています。

乳がん診断薬市場は、検出ソリューションの強化が急務であることを背景に急速に進化しています。乳がんは初期症状を示さないことが多いため、AI技術は患者の診断に対処する上で極めて重要になってきており、Paragon Biosciences LLCが乳房診断用AIシステムのFDA認可を目指すQlarity Imaging LLCを立ち上げたことがその例です。様々な画像診断法でAIを活用する企業が増えており、ヘルスケアプロバイダーに費用対効果の高いソリューションを提示しています。インドにおける富士フイルムの健診センター「NURA」のような民間診断センターの台頭は、公的病院へのアクセスが限られているためそれに代わる画像診断サービスの需要増へ対応したものです。さらに、発展途上地域では、Siemens、GE Healthcare、Philipsによる高品質な再生医療システムの普及に向けた業界の取り組みに支えられ、改装された画像診断機器が費用対効果の高い選択肢として人気を集めています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術の進歩

乳がん診断薬市場規模：タイプ別

• 市場概要
• 画像診断
  • マンモグラフィー
  • MRI
  • 超音波
  • PET/CT
• 生検
• ゲノム検査
• 血液検査
• その他

乳がん診断薬市場規模：製品別

• 市場概要
• プラットフォームベースの製品
  • 次世代シーケンシング
  • マイクロアレイ
  • PCR
  • その他
• 計測機器ベースの製品
  • 画像診断
  • 生検

乳がん診断薬市場規模：がんの種類別

• 市場概要
• 乳管がん（非浸潤性乳管がん）
• 浸潤性乳管がん
• 炎症性乳がん
• 転移性乳がん

乳がん診断薬市場規模：用途別

• 市場概要
• スクリーニング
• 診断と予測
• 予後
• 調査
• その他

乳がん診断薬市場規模：エンドユーザー別

• 市場概要
• 病院・クリニック
• 診断センター
• 医療研究室
• その他

乳がん診断薬市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Hologic（USA）
• Natera（USA）
• Siemens Healthineers（Germany）
• Leica Biosystems（Germany）（Parent company：Danaher Corporation）
• Roche Diagnostics（Switzerland）
• GE Healthcare（USA）
• Philips Healthcare（Netherlands）
• Abbott Laboratories（USA）
• Thermo Fisher Scientific（USA）
• Becton, Dickinson and Company（USA）
• Agilent Technologies（USA）
• Illumina（USA）
• PerkinElmer（USA）
• Qiagen（Germany）
• Bio-Rad Laboratories（USA）
• Cepheid（USA）（Parent company：Danaher Corporation）
• Myriad Genetics（USA）
• Fujifilm Holdings Corporation（Japan）
• Canon Medical Systems Corporation（Japan）
• Hitachi Medical Systems（Japan）

結論と提言

Breast Cancer Diagnostics Market size was valued at USD 5.6 billion in 2023 and is poised to grow from USD 6.04 billion in 2024 to USD 11.01 billion by 2032, growing at a CAGR of 7.8% during the forecast period (2025-2032).

The breast cancer diagnostics market is evolving rapidly, driven by the urgent need for enhanced detection solutions. With breast cancer often presenting no early symptoms, AI technologies are becoming pivotal in addressing patient diagnostics, exemplified by Paragon Biosciences LLC's launch of Qlarity Imaging LLC, which aims for FDA clearance of an AI system for breast diagnostics. Companies are increasingly utilizing AI across various imaging modalities, presenting cost-effective solutions for healthcare providers. The rise of private diagnostic centers, like FUJIFILM Corporation's NURA in India, is a response to increased demand for imaging services, driven by public hospital limitations. Additionally, in developing regions, refurbished imaging equipment is gaining traction as a cost-effective alternative, supported by industry initiatives from Siemens, GE Healthcare, and Philips to promote quality refurbished systems.

Top-down and bottom-up approaches were used to estimate and validate the size of the Breast Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Breast Cancer Diagnostics Market Segments Analysis

Global Breast Cancer Diagnostics Market is segmented by Type, Product, Cancer Type, Application, End-user and region. Based on Type, the market is segmented into Imaging, Biopsy, Genomic Tests, Blood Tests and Others. Based on Product, the market is segmented into Platform-based Products and Instrument-based Products. Based on Cancer Type, the market is segmented into Ductal carcinoma in situ, Invasive ductal carcinoma, Inflammatory breast cancer and Metastatic breast cancer. Based on Application, the market is segmented into Screening, Diagnostic and Predictive, Prognostic, Research and Others. Based on End-user, the market is segmented into Hospitals & Clinics, Diagnostic Centers, Medical Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Breast Cancer Diagnostics Market

The Breast Cancer Diagnostics market is primarily driven by technological advancements, including state-of-the-art imaging techniques, molecular diagnostic methods, and biomarker assays. These innovations have greatly enhanced the accuracy and efficiency of breast cancer detection and diagnosis, leading to their widespread adoption among healthcare professionals. The continuous development of sophisticated diagnostic tools not only improves patient outcomes but also propels market growth by meeting the increasing demand for reliable and effective breast cancer screening solutions. As these technologies evolve, they further reinforce the importance of early detection and timely intervention in combating breast cancer.

Restraints in the Breast Cancer Diagnostics Market

Cultural beliefs and the social stigma associated with breast cancer can significantly hinder women's willingness to participate in screening and diagnostic tests. These factors often lead to a reluctance to seek necessary medical attention, ultimately affecting the rates of early detection and diagnosis. As a result, many women might avoid or postpone crucial evaluations due to fear, misconceptions, or societal pressures. This resistance not only increases the risk of late-stage diagnosis but also poses a challenge to the overall effectiveness of breast cancer diagnostics in improving patient outcomes. Overcoming these barriers is essential for enhancing early intervention and promoting better health practices.

Market Trends of the Breast Cancer Diagnostics Market

The breast cancer diagnostics market is witnessing a significant trend towards the adoption of liquid biopsies, which analyze circulating tumor cells and cell-free DNA from blood samples. This non-invasive approach is particularly appealing for early detection and real-time monitoring of treatment efficacy, thereby enhancing patient outcomes. As healthcare providers and patients increasingly seek alternatives to traditional tissue biopsies, the demand for liquid biopsy solutions is surging. Coupled with advancements in molecular biology and personalized medicine, this trend is expected to drive innovation, investment, and growth within the breast cancer diagnostics landscape, positioning liquid biopsies as a cornerstone in future clinical practices.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Breast Cancer Diagnostics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Imaging
  • Mammography
  • MRI
  • Ultrasound
  • PET/CT
• Biopsy
• Genomic Tests
• Blood Tests
• Others

Global Breast Cancer Diagnostics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Platform-based Products
  • Next-generation Sequencing
  • Microarrays
  • PCR
  • Others
• Instrument-based Products
  • Imaging
  • Biopsy

Global Breast Cancer Diagnostics Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Ductal carcinoma in situ
• Invasive ductal carcinoma
• Inflammatory breast cancer
• Metastatic breast cancer

Global Breast Cancer Diagnostics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Screening
• Diagnostic and Predictive
• Prognostic
• Research
• Others

Global Breast Cancer Diagnostics Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Diagnostic Centers
• Medical Laboratories
• Others

Global Breast Cancer Diagnostics Market Size & CAGR (2025-2032)

• North America (Type, Product, Cancer Type, Application, End-user)
  • US
  • Canada
• Europe (Type, Product, Cancer Type, Application, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Product, Cancer Type, Application, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Product, Cancer Type, Application, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Product, Cancer Type, Application, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Hologic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leica Biosystems (Germany) (Parent company: Danaher Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cepheid (USA) (Parent company: Danaher Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Holdings Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canon Medical Systems Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hitachi Medical Systems (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations